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ORIGINAL RESEARCH ARTICLE
BACKGROUND: Pulmonary arterial hypertension (PAH) is a heterogeneous 
disorder with high mortality.
METHODS: We conducted a comprehensive study of plasma metabolites 
using ultraperformance liquid chromatography mass spectrometry to 
identify patients at high risk of early death, to identify patients who respond 
well to treatment, and to provide novel molecular insights into disease 
pathogenesis.
RESULTS: Fifty-three circulating metabolites distinguished well-phenotyped 
patients with idiopathic or heritable PAH (n=365) from healthy control 
subjects (n=121) after correction for multiple testing (P<7.3e-5) and 
confounding factors, including drug therapy, and renal and hepatic 
impairment. A subset of 20 of 53 metabolites also discriminated 
patients with PAH from disease control subjects (symptomatic patients 
without pulmonary hypertension, n=139). Sixty-two metabolites were 
prognostic in PAH, with 36 of 62 independent of established prognostic 
markers. Increased levels of tRNA-specific modified nucleosides 
(N2,N2-dimethylguanosine, N1-methylinosine), tricarboxylic acid cycle 
intermediates (malate, fumarate), glutamate, fatty acid acylcarnitines, 
tryptophan, and polyamine metabolites and decreased levels of steroids, 
sphingomyelins, and phosphatidylcholines distinguished patients from 
control subjects. The largest differences correlated with increased risk of 
death, and correction of several metabolites over time was associated 
with a better outcome. Patients who responded to calcium channel blocker 
therapy had metabolic profiles similar to those of healthy control subjects.
CONCLUSIONS: Metabolic profiles in PAH are strongly related to survival 
and should be considered part of the deep phenotypic characterization of 
this disease. Our results support the investigation of targeted therapeutic 
strategies that seek to address the alterations in translational regulation 
and energy metabolism that characterize these patients.
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Pulmonary arterial hypertension (PAH) is a progres-sive vascular disorder that leads to increased pulmonary vascular resistance, right ventricular 
dysfunction,1 and premature death.2 The pathogenesis 
of the vascular pathology is poorly understood.3,4 Sev-
eral genetic mutations have been reported in hereditary 
and isolated idiopathic presentations of PAH, providing 
insight into perturbed signaling pathways,5,6 and ge-
nome sequencing of clinically well-characterized patient 
cohorts is underway in anticipation of finding new mu-
tations. A complementary approach to identifying the 
molecular drivers of PAH is to conduct deep molecular 
phenotyping of patients beyond standard clinical tests.
Metabolomic technologies such as ultraperformance 
liquid chromatography mass spectrometry enable the 
detection and semiquantitative measurement of hun-
dreds of unique metabolites, representing a broad range 
of metabolic pathways, in small volumes of biofluids.7 
These approaches have identified differences in circu-
lating metabolites that distinguish physiological and dis-
ease states such as diabetes mellitus and systemic car-
diovascular disorders and predict clinical outcomes.8–10 
So far, few metabolomics studies have been undertaken 
in patients with pulmonary vascular disease. Evidence of 
abnormal oxidation, arginine, and sphingosine pathways 
has been found from mass spectrometry analysis of lung 
tissue from patients with PAH,11,12 and analysis of breath 
samples showed that exhaled volatile compounds dis-
criminate between patients with severe idiopathic PAH 
and healthy volunteers.13 A targeted analysis of 105 
circulating plasma metabolites in PAH, primarily amino 
acids, nucleosides, and their derivatives, showed that 
abnormal levels of tryptophan, purine, and tricarboxylic 
acid (TCA) cycle metabolites correlated to hemodynamic 
measures.14
In this study, we used a broad metabolomics platform 
to analyze 1416 metabolites in plasma from patients 
with idiopathic or heritable PAH (n=365) in 3 distinct co-
horts and compared circulating levels with both healthy 
(n=121) and disease (n=139) control subjects. We iden-
tified specific metabolites that both discriminate patients 
with PAH from healthy and disease control subjects and 
independently predict survival. These metabolites in-
cluded several modified nucleosides specific to transfer 
RNAs that indicate alterations in cell proliferation and 
translation of disease-related proteins, as well as several 
constituents of energy metabolism.
METHODS
Sample Collection
Samples were obtained from patients with idiopathic or herita-
ble PAH attending the National Pulmonary Hypertension Service 
at Hammersmith Hospital, London, between 2002 and 2015 
and from patients recruited from other UK national centers as 
part of the National Cohort Study of Idiopathic and Heritable 
Pulmonary Arterial Hypertension (ClinicalTrials.gov. Unique 
identifier: NCT01907295). Control plasma samples were 
obtained from healthy subjects and disease control subjects, 
the latter being symptomatic patients presenting to the service 
but in whom pulmonary hypertension was excluded by cardiac 
catheterization. The diagnosis of PAH was based on standard 
criteria from the most recent guidelines.1 Vasoresponders 
were defined as those whose mean pulmonary artery pressure 
dropped >10 mm Hg to <40 mm Hg with preserved cardiac 
output in response to an acute pulmonary vasodilator chal-
lenge and remained stable on calcium channel blocker therapy 
alone for at least 1 year.1 Whole-genome sequencing data from 
the UK National Institute of Health Research BRIDGE consor-
tium (Biomedical Research Centres Inherited Diseases Genetic 
Evaluation) were used to determine which patients had known 
pathogenic mutations in the gene encoding the bone morpho-
genetic protein type II receptor (BMPR2).5
Venous blood samples were drawn from the antecubital 
fossa and collected in EDTA Vacutainer tubes (BD, Oxford, UK), 
immediately put on ice, centrifuged (1300g, 15 minutes) within 
30 minutes, and stored at −80°C until required. World Health 
Organization functional class and 6-minute walk distance at 
the sample date and clinical biochemical data (within 30 days) 
were recorded. All subjects provided informed written consent, 
and local research ethics committees approved the study. A 
subset of patients consented to provide additional samples at 
later dates while attending follow-up clinical appointments.
Clinical Perspective
What Is New?
• This study provides a comprehensive analysis of cir-
culating metabolite levels in patients with pulmonary 
arterial hypertension (PAH) and control subjects.
• It is the first study to relate metabolite levels to clini-
cal outcomes in PAH.
• Increases in circulating modified nucleosides origi-
nating from transfer RNAs, energy metabolism inter-
mediates, tryptophan, and polyamine metabolites 
and decreased steroids, sphingomyelins, and phos-
phatidylcholines independently discriminate patients 
with PAH from control subjects and predict survival.
• Correction of metabolite levels over time is linked to 
better clinical outcomes, and patients who respond 
well to calcium channel blocker therapy have meta-
bolic profiles comparable to those of healthy control 
subjects.
What Are the Clinical Implications?
• Energy metabolism and stress-response pathways 
are disturbed in PAH.
• Monitoring plasma metabolites that report on these 
pathways over time could be useful to assess dis-
ease progression and response to therapy.
• Therapeutic strategies targeted against metabolic dis-
turbances in PAH, particularly translational regulation 
and energy metabolism, merit further investigation.
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Metabolomics
Metabolomic profiling by ultraperformance liquid chroma-
tography mass spectrometry was conducted by Metabolon 
(Durham, NC),7 which provided semiquantitative assessment 
of 949 named and 467 unnamed metabolite levels, annotated 
with pathways. Named compounds identified from mass and 
fragmentation analysis but yet to be confirmed with standards 
are indicated by asterisks. Details can be found in the online-
only Data Supplement.
Angiogenin
Plasma angiogenin levels were determined by ELISA (reference 
No. DAN00, R&D Systems, Abingdon, UK) per the manufactur-
er’s guidelines, with EDTA plasma diluted 1:800 before assay.
Statistical Analysis
To prevent skewing of results by outliers, initial group compari-
sons between control subjects and patients were performed 
with nonparametric Mann Whitney U tests. Before modeling, 
metabolites with distributions that were not normal were either 
transformed by log10 or power transformations (x
Y, with Y from 
−2 to 2 in 0.5 steps, as performed for Box-Cox transforma-
tions15), whichever best normalized the data on the basis of 
Kolmogorov-Smirnov tests, or ranked if no test met P>0.05. 
Samples for which metabolites were undetected were imputed 
with the minimum detected level for the metabolite. Data in all 
groups were z score transformed on the basis of the mean 
and standard deviation in all healthy control subjects for ease 
of comparisons. Data are presented as absolute numbers, per-
centages, or mean or median (±SD) and percentile range.
Linear regression analysis was conducted to assess the 
relationships between metabolite levels, diagnoses, and 
potential confounders to determine whether differences in 
metabolite levels between groups were independent of age, 
sex, ethnicity, body mass index, drugs, and renal and hepatic 
dysfunction. In the disease control and PAH cohorts, preserved 
renal function was defined as creatinine <75 µmol/L, and pre-
served liver function was defined as bilirubin <21 µmol/L. 
Logistic regression was conducted to determine metabolites 
that independently distinguished between diagnostic groups. 
Orthogonal partial least squares discriminant analysis model-
ing was used to test the performance of these metabolites. R2 
scores indicate model performance, and Q2 scores estimate 
reproducibility on the basis of cross-validation (subjects were 
divided into 7 groups, and their diagnosis was predicted on 
the basis of the other subjects in 7 analyses). Pathway enrich-
ment analysis was conducted on discriminating and prognostic 
metabolites with the Fisher’s exact test.
All survival analyses were performed with the use of time 
from sampling to death/census. Cox regression analysis was 
used to identify prognostic predictors, with proportional hazard 
assumptions tested and Kaplan-Meier plots used to illustrate 
events from time of sampling in relation to metabolite levels. 
Receiver-operating characteristic curves were used to assess 
discriminating and prognostic values of metabolites against 
diagnosis and all-cause mortality, respectively. Hierarchical 
clustering on the basis of euclidean distances was used to 
assess whether metabolites and patients clustered by func-
tional pathways and phenotypes, respectively.
Network analysis was performed by calculating second-
order Spearman rank correlations with ParCorA16,17 and visual-
ized with Cytoscape.18 “Hub” nodes are metabolites with the 
most “edges” (correlations) to other metabolites.
Statistical analysis was performed with IBM SPSS Statistics 
22 (International Business Machines Corp, New York, NY), 
Matlab (Matrix Laboratory, MathWorks, Natick, MA), Microsoft 
Excel (Microsoft, Redmond, WA), SIMCA-P software, (Umetrics, 
Umea, Sweden), and R with RStudio and associated packages.19
RESULTS
Metabolites Distinguishing Between PAH and 
Control Subjects
We first compared plasma metabolite profiles from 116 
consecutive patients with idiopathic or heritable PAH at-
tending Hammersmith Hospital between November 2011 
and August 2013 and 58 healthy control subjects (Table 
1). To minimize confounding factors, only patients with 
PAH who were 19 to 70 years of age were compared 
with age- and sex-matched healthy control subjects in 
this analysis. Results were validated in 75 patients with 
PAH recruited between 2002 and 2015 against a sepa-
rate control group (n=63). A second validation analysis 
used 174 patients with PAH recruited from other special-
ist centers in the United Kingdom from August 2013 to 
June 2015 and compared with all control subjects. Me-
tabolites identified as xenobiotics or detected in <95% 
of samples were excluded from the analysis, leaving 686 
well-quantified biological metabolites.
Circulating levels of 97 metabolites distinguished 
PAH from healthy subjects in all 3 analyses after Bon-
ferroni correction (P<7.3e-5). Of these metabolites, 53 
distinguished healthy control and PAH subjects after cor-
rection for potential confounders, including age, sex, 
ethnicity, body mass index, creatinine, bilirubin, and 
drug therapies (P<0.05; Table I in the online-only Data 
Supplement and Figure 1). The most common confound-
ers associated with metabolite levels were liver function 
(bilirubin) and renal function (creatinine). To determine 
whether these metabolite differences could be detected 
before the initiation of PAH therapies, we performed a 
subanalysis comparing 40 patients who were treatment 
naïve at the time of sampling, and all 53 metabolites 
distinguished this group from healthy control subjects 
(P<0.05; Table I in the online-only Data Supplement). 
Patients with pathogenic BMPR2 mutations (n=42) had 
metabolite levels similar to PAH patients without these 
mutations (Figure I and Table I in the online-only Data 
Supplement).
Given that many metabolic alterations might occur in 
a chronic disease such as PAH, we set out to prioritize 
more disease-specific metabolites by comparing the pa-
tients with PAH with disease control subjects, the latter 
comprising symptomatic patients in whom pulmonary 
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Table.  Cohort Characteristics
Discovery Validation 1 Validation 2
HCs (n=58) DCs (n=70)
PAH (19–70 y) 
(n=88)
PAH (>70 y) 
(n=28) HCs (n=63) DCs (n=69) PAH (n=75)
PAH-2 
(n=174)
Age at sampling, y 48±13.5 56.5±15.9 48.1±13.8 75.9±4.8 49.1±16.1 55.9±18.5 52±16.3 52±15
Female:male (ratio) 38:20 (1.9:1) 48:22 (2.2:1) 61:27 (2.3:1) 19:9 (2.1:1) 40:23 (1.7:1) 48:21 (2.3:1) 52:23 (2.3:1) 127:47 (2.7:1)
Ethnicity, % nonwhite 32.5 56.9 17.0 14.8 38.1 44.1 18.6 8.1
BMI, kg/m2 30.5±10.5 27.9±6 28.7±8.2 27.9±5.7 26±4.1 27.4±5.9 30.1±7.2 29.2±7
Baseline hemodynamics at diagnosis
  Pulmonary capillary 
wedge pressure, 
mm Hg
 11.6±4.5 11.9±6 12.1±4.6  10.8±3.5 10.8±4.9 9.4±3.8
  Mean pulmonary 
artery pressure, 
mm Hg
 19.3±4.1 53.1±14.3 46.3±14.6  19.1±4.7 53.7±11.1 56.2±15.2
  Pulmonary vascular 
resistance, Woods 
units
  12.3±5.7 8.6±4.7   12.4±5.8 13±6.4
  Mean right atrial 
pressure, mm Hg
 7.3±3.4 10.0±5.7 9.3±4.9  6.3±3.2 11.8±5.8 9.2±5.3
  Cardiac output, L/min   4.4±1.7 4.5±1.8   4.0±1.7 4.0±1.3
Functional status and pathology
  6-min walk  
distance, m
  279.4±153.4 197.9±158.7   271.3±169.5 334.8±119.0
  WHO functional  
class I/II/III/IV
  2/11/65/10 0/2/23/1   0/7/52/9 2/24/119/18
  RDW, %   14.8±2.1 15.0±1.1   16.0±2.9 14.7±3.3
  NT-proBNP, pmol/L   735±882 1137±1123    895±1244
  Creatinine, μmol/L  76.3±21.8 81.2±29.1 107.6±35.7  87±40.6 92.7±32.6 89.9±25.1
  Bilirubin, μmol/L  13.9±13.9 15.6±10.7 12.4±8.5  16.3±22.8 17.2±10.4 12.1±9.0
Comorbidities (%)
  Asthma/COPD  17.1 11.4 11.1  11.6 17.1 17.6
  Diabetes mellitus  8.6 17.0 48.1  13.0 24.3 14.2
  CAD/IHD  10.0 12.5 37.0  11.6 12.9 8.3
  AF/flutter  14.3 18.2 25.9  17.4 8.6 5.9
  Systemic 
hypertension
 22.9 19.3 77.8  36.2 22.9 17.2
  Hypercholesterolemia/
lipidemia
 12.9 12.5 22.2  10.1 15.7 6.5
Drug therapy (%)
  Anticoagulation  32.9 71.6 78.6  34.8 65.3 66.7
  PDE5 inhibitors  0.0 65.9 67.9  0.0 48.0 77.8
  ERAs  0.0 48.0 30.8  0.0 33.8 64.3
  Diuretics  12.9 37.5 75.0  21.7 53.3 54.4
  Aldosterone 
antagonists
 7.1 31.8 21.4  1.4 34.7 8.2
  Statins/lipid-lowering 
drugs
 25.7 22.7 57.1  33.3 24.0 24.0
(Continued )
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hypertension had been excluded. We again adopted a 
discovery-and-validation design with 2 groups of dis-
ease control subjects (n=70 and 69). A subset (20 of 
53) of the metabolites distinguished patients with PAH 
from disease control subjects after correction for po-
tential confounders (P<0.05; Table I in the online-only 
Data Supplement). These “PAH-specific” differences in 
metabolites included increases in purine, polyamine, and 
TCA cycle metabolites and decreases in phosphocho-
lines and sphingomyelins (Figure 2A), with network analy-
sis showing the importance of hub metabolites N2,N2-
dimethylguanosine and malate (Figure 2B).
Discriminant Analyses to Distinguish PAH and 
Control Groups
To identify a minimal set of metabolites that could in 
combination best distinguish patients with PAH, we 
performed logistic regression analysis. We found that 
7 of 53 metabolites—dehydroisoandrosterone sulfate 
(DHEA-S), methionine sulfone, N1-methylinosine, oleoyl-
carnitine, palmitoylcholine, sphingomyelin (d18:1/20:0, 
d16:1/22:0)*, and X-24513—independently distin-
guished patients with PAH (19–70 years of age) and 
healthy subjects in the discovery analysis with 90% ac-
curacy in an orthogonal partial least squares discrimi-
nant analysis (R2=0.64, Q2=0.61). This model classified 
healthy subjects and patients with PAH in the 2 validation 
analyses with 89% and 84% accuracy, respectively. In 
addition, 90% (9 of 10) of PAH vasoresponders in the 
discovery cohort had metabolite levels typical of healthy 
control subjects (Figure 3A and 3B).
Four of the 20 PAH-specific metabolites—N-acety-
laspartate, octadecanedioate, palmitoylcholine, and X-
13737—distinguished patients with PAH and disease 
control subjects with 83% accuracy in the discovery 
Figure 1. Analysis flow chart.  
Summary of analytic workflow showing 
numbers of metabolites that distinguish 
patients with pulmonary arterial hyperten-
sion (PAH) from control subjects and/or are 
prognostic in PAH. NT-proBNP indicates  
N-terminal brain natriuretic peptide; and 
RDW, red cell distribution width.
  CCBs  10.0 14.8 28.6  24.6 14.7 21.1
  Cardiac glycosides  7.1 17.0 14.3  8.7 21.3 9.4
  Antidiabetic drugs  8.6 12.5 35.7  10.1 18.7 9.4
  Prostanoids  0.0 9.1 0.0  0.0 6.7 33.3
  Iron replacement 
therapy
 4.3 13.6 25.0  5.8 4.0 10.5
  ACE inhibitors  27.1 17.0 60.7  37.7 28.0 16.4
Mean±SD, counts or percentages are given. ACE indicates angiotensin-converting enzyme; AF, atrial fibrillation; BMI, body mass index; CAD, 
coronary artery disease; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease; DC, disease control; ERA, endothelin receptor 
antagonist; HC, healthy control; IHD, ischemic heart disease; NT-proBNP, N-terminal brain natriuretic peptide at time of sample; PAH, pulmonary arterial 
hypertension; PDE5, phosphodiesterase 5; RDW, red cell distribution width; and WHO, World Health Organization. Ethnicity is shown for subjects who 
self-declared.
Table. Continued
Discovery Validation 1 Validation 2
HCs (n=58) DCs (n=70)
PAH (19–70 y) 
(n=88)
PAH (>70 y) 
(n=28) HCs (n=63) DCs (n=69) PAH (n=75)
PAH-2 
(n=174)
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A
B
Figure 2. Metabolites that discriminate patients with pulmonary arterial hypertension pulmonary arterial  
hypertension (PAH) from control subjects.  
A, Average metabolite levels in PAH and control subjects for 20 metabolites found to significantly distinguish patients with PAH 
from both healthy and disease control subjects independently of potential confounders. Values plotted are z scores calculated 
from the mean and standard deviation of all healthy volunteers in the study. Negative values indicate metabolites at lower levels 
in patients vs healthy control subjects, and positive values indicate higher levels of metabolites in patients. For the discovery 
analysis, only data from patients with PAH who were 19 to 70 years of age are plotted; for the validation analysis, all patients 
data are shown. B, Network analysis of the same 20 metabolites on the basis of second-order correlations. Line thickness 
indicates strength of correlations (all P<0.0001). *Probable metabolite identity but unconfirmed (see Methods). DHE indicates 
docosahexaenoyl; DHEA-S, dehydroisoandrosterone sulfate; DPE, docosapentaenoyl; EPE, eicosapentaenoyl; GPC, glycerophos-
phocholine; and SM, sphingomyelin.
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analysis (R2=0.49, Q2=0.47). This model classified dis-
ease control subjects and patients with PAH in the 2 
validation analyses with 69% and 67% accuracy, respec-
tively (Figure 3C and 3D).
Survival Analysis of Plasma Metabolites of  
Interest in PAH
We hypothesized that metabolites most closely related to 
the disease pathobiology would be associated with clinical 
outcomes. To identify metabolites associated with disease 
progression and mortality, we performed survival analy-
ses. Twenty-eight of 116 and 25 of 75 patients died in the 
discovery and first validation PAH groups with an average 
follow-up of 3.3±1.0 and 4.5±4.0 years, respectively. 
The length of patient follow-up in the second validation 
cohort was insufficient to permit analysis. After correcting 
for creatinine and diuretic use, no other potentially con-
founding factor was associated with survival. Of the 686 
well-quantified metabolites, 640 met the assumptions of 
Cox regression analysis, and 62 of these were prognostic 
after accounting for creatinine and diuretic use in both 
analyses. Receiver-operating characteristic analysis at 3 
years of follow-up confirmed that these metabolites were 
prognostic and identified optimal cutoffs (P<0.05; Figure 
II in the online-only Data Supplement).
To identify metabolites that report on novel pathways 
independently of current prognostic estimates, we com-
pared the 62 prognostic metabolites with 3 markers 
previously found to best predict survival in our patients, 
C D
A B
Discovery
Validation
Validation-2
Analysis AUC Sig. 95% CI
Discovery 0.990 2E-22 0.979 - 1.000
Validation-1 0.950 2E-19 0.912 - 0.989
Validation-2 0.939 1E-37 0.914 - 0.964
Discovery
Validation
Validation-2
Analysis AUC Sig. 95% CI
Discovery 0.914 4E-18 0.869 - 0.958
Validation-1 0.723 2E-06 0.647 - 0.816
Validation-2 0.747 6E-14 0.692 - 0.801
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Figure 3. Discriminant analysis models on the basis of low numbers of metabolites distinguish patients with 
pulmonary arterial hypertension (PAH) from control subjects.  
A and C, Dot plots showing individual subjects’ model scores for healthy control subjects (HC), patients with PAH, vasore-
sponders, and disease control subjects (DC) in discovery and validation analyses. Metabolites were selected by logistic regres-
sion of PAH-HC (A) and PAH-DC (C) comparisons. B and D, Receiver-operating characteristic curves showing the performance of 
models in distinguishing PAH from HC (B) and DC (D) subjects. AUC indicates area under the curve; and CI, confidence interval.
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namely N-terminal brain natriuretic peptide, 6-minute 
walk distance, and red cell distribution width.20 Thirty-
six of 62 of the metabolites were independent of these 
measures (P<0.05; Figure 4A and Table II in the online-
only Data Supplement), and network analysis indicated 
2 main clusters with hub metabolites, including again, 
among others, N2,N2-dimethylguanosine (Figure 4B).
Enrichment and Clustering of Metabolites  
of Interest
The above analyses identified and validated, after control-
ling for confounders, a total of 99 metabolites that were 
either discriminating or prognostic in PAH, representing 
25 metabolic pathways. Six pathways in particular were 
enriched with metabolites of interest, including fatty acid 
(acyl carnitines), polyamine, and nucleoside metabolism 
(P<0.05; Table III in the online-only Data Supplement). 
Sixteen of these metabolites both discriminated PAH and 
were prognostic; these, along with the 3 other metabo-
lites selected by logistic regression modeling to best dis-
tinguish patients with PAH and healthy subjects, clustered 
into defined metabolic pathways (Figure 5).
Analysis of Serial Samples
Changes in metabolite levels in individuals over time may in-
dicate pathways that report clinical improvement or the cor-
rection of which leads to improved outcomes. We analyzed 
serial samples from 86 patients who were followed up for 
a minimum of 1 year (median, 1.50 years; interquartile 
range, 1.33–2.95 years) after the second sample. Twenty-
nine patients died during follow-up. Changes in metabo-
lite levels between the 2 samples (median time between 
samples, 1.75 years; interquartile range, 1.07–2.58 years) 
were compared between survivors and nonsurvivors.
Changes in 27 of 99 metabolites, including several 
modified amino acids and nucleosides, were significantly 
different between survivors and nonsurvivors (P<0.05). 
Receiver-operating characteristic analysis confirmed 
these associations (Table IV in the online-only Data Sup-
plement) and identified prognostic cut-offs (Figure 6).
Association of Elevated Modified Nucleosides 
With Elevated Plasma Angiogenin
Modified nucleosides can be released into the circulation 
during stress after cleavage of transfer RNAs (tRNAs) 
by the ribonuclease angiogenin.21 To determine whether 
this mechanism was relevant to PAH, we measured plas-
ma angiogenin in a representative subset of age- and 
sex-matched healthy control subjects and patients with 
PAH from the discovery analysis (Table V in the online-
only Data Supplement). Angiogenin levels were elevated 
in plasma from patients with PAH and correlated with 
N2,N2-dimethylguanosine levels (ρ=0.49, P<0.001; Fig-
ure 7). The strength of correlation was similar in male 
and female subjects (data not shown).
DISCUSSION
This study represents the most comprehensive analysis 
of circulating metabolites in patients with PAH to date. 
It is the first to robustly identify and validate differences 
in comparison to both healthy and symptomatic disease 
control subjects without pulmonary hypertension and 
to associate metabolic profiles with outcomes in PAH, 
strengthening the evidence that the pathways identified 
could be important modifiers of disease progression. 
Changes in the levels of metabolites over time were as-
sociated with survival in a direction that suggests that 
correction of these disturbances is linked to improved 
outcomes. In agreement with this, patients defined as 
vasoresponders, who have excellent outcomes on calci-
um channel blocker therapies, demonstrated metabolic 
profiles more similar to those of healthy control subjects 
than to other patients. Metabolic profiles seen in incident 
cases were similar to those with established PAH, em-
phasizing that metabolic dysregulation is not corrected 
in the majority of cases by current therapy.
Modified Nucleosides
Two of the most robust distinguishing and prognostic dif-
ferences identified in patients with PAH were increased 
levels of N1-methylinosine and N2,N2-dimethylguano-
sine. These are recognized epigenetic, posttranscrip-
tional modifications of tRNA,21–23 and other tRNA modi-
fications also found to be increased and prognostic 
included pseudouridine, N6-carbamoylthreonyladenosine 
and N1-methyladenosine. N2,N2-dimethylguanosine is 
found in the majority of tRNAs at position 26, upstream 
of the anticodon sequence at positions 34 to 36, and 
promotes the folding of tRNAs toward the classical clo-
verleaf structure.24 N1-methylinosine is found 3′ adjacent 
to the anticodon at position 37 of eukaryotic tRNAs and 
is formed from inosine by a specific S-adenosylmethi-
onine–dependent methylase.25 Increased serum and 
urine levels of N2,N2-dimethylguanosine, as well as 
pseudouridine and 1-methylinosine, have been observed 
in multiple solid tumor malignancies26 and may reflect 
the general upregulation of the translational apparatus, 
including tRNA turnover, in hyperproliferative cancerous 
cells.27 Increased circulating 1-methyladenosine has also 
been shown to be an early indicator of oxidative stress, 
cell damage, and mortality in kidney disease.28
Intracellular tRNA pools are dynamically regulated. For 
example, under stress, tRNAs required for the translation 
of stress response proteins are preferentially expressed.21 
The altered levels of specific nucleoside modifications in 
patients with PAH may reflect preferential expression of 
the tRNAs that harbor them as part of a switch toward 
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A
B
Figure 4. Prognostic metabolites independent of established risk factors.  
A, Hazard ratios after correction for creatinine and diuretic use of 36 metabolites that were prognostic in patients with pulmonary 
arterial hypertension independently of red cell distribution width, N-terminal brain natriuretic peptide, and 6-minute (Continued )
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translation of disease-related proteins. In addition, stress-
induced cleavage of tRNA produces fragments that prop-
agate the stress response and interfere with eukaryotic 
initiation factors-4G and -4F.21 Furthermore, eukaryotic ini-
tiation factor-2α kinase-4 (GCN2), which prevents eukary-
otic initiation factor-2α from interacting with the initiating 
Met-tRNA, suppressing general protein synthesis and ac-
tivating stress-inducible transcription factors, is mutated 
Figure 5. Hierarchical clustering of 19 discriminating and prognostic metabolites in patients with pulmonary 
arterial hypertension (PAH).  
A, Venn diagram shows overlap between metabolites that discriminate patients with PAH from healthy control subjects in all 
3 cohorts from logistic regression between patients with PAH and healthy control subjects and prognostic metabolites in the 
discovery and first validation cohorts. B, Clustering of the 19 overlapping metabolites from A is shown between healthy control 
subjects (HC; n=58), PAH survivors (n=110, alive at 3 years after sample), and nonsurvivors (n=24) in the discovery analysis. Red 
indicates metabolite levels that are increased (and blue levels that are decreased) in patients with PAH vs control subjects. *Prob-
able metabolite identity but unconfirmed (see Methods). ‡Metabolites also distinguish PAH from disease control subjects. DHEA-S 
indicates dehydroisoandrosterone sulphate; EPE, eicosapentaenoyl; GPC, glycerophosphocholine; and SM, sphingomyelin.
Figure 4 Continued. walk distance. Hazard ratios indicate the risk of a change in each metabolite of 1 SD for ease of compari-
son. Patients of all ages were included in both the discovery and validation survival analyses. B, Network analysis of the same 
36 metabolites on the basis of second-order correlations. Line thickness indicates strength of correlations (all P<0.0001). Red 
lines indicate negative correlations. *Probable metabolite identity but unconfirmed (see Methods). DHE indicates docosahexae-
noyl; DHEA-S, dehydroisoandrosterone sulfate; DPE, docosapentaenoyl; EPE, eicosapentaenoyl; GPC, glycerophosphocholine; 
GPE, glycerophosphoethanolamine; Met, Cys, SAM and Taur, methionine, cysteine, S-adenosylmethionine and taurine; and SM, 
sphingomyelin.
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and causally implicated in some cases of pulmonary 
vascular disease.29 Mutations in tRNA genes themselves 
have also been reported to cause pulmonary hyperten-
sion driven by mitochondrial dysfunction.30
The initial cleavage of tRNAs is mediated by angio-
genin,21 which we showed to be elevated in the plasma of 
patients with PAH in concert with elevated levels of modi-
fied nucleosides. Angiogenin is also upregulated in cancer 
cells, mediating angiogenesis, cell proliferation, and pro-
tection from apoptosis,31 and is increased in breath con-
densates from patients with pulmonary hypertension,32 
indicating a possible pulmonary origin in this disease. 
Angioproliferative plexiform vascular lesions are charac-
teristic of advanced PAH, and the proangiogenic activity 
of angiogenin is inhibited by mutation of its ribonuclease 
active site,33 suggesting that elevated angiogenin and 
nucleoside levels may report patients developing this type 
of pulmonary vascular remodeling. Alterations in tRNA bi-
ology appear to be capable of driving the development 
of rare forms of pulmonary hypertension and are closely 
linked to the progression of PAH. Circulating levels of 
modified nucleosides may reflect increases in both pulmo-
nary vascular cell proliferation and stress.
Energy Metabolism
Significant alterations were observed in several path-
ways related to cellular energy production, with accu-
mulation of multiple acylcarnitines, glutamate, and TCA 
cycle intermediates. Their accumulation in patients with 
PAH may represent a failed attempt to increase utility of 
fatty acids as an energy source, perhaps reflecting the 
inability of fatty acid beta-oxidation to keep pace with 
the demands of the overburdened right ventricle. Gluta-
A B
C D
Survivors Non-survivors
P<0.0001
Survivors Non-survivors
P<0.0001
Figure 6. Analysis of serial samples.  
A, Receiver-operating characteristic analysis of changes in metabolite levels and survival status at last follow-up. B and D, 
Changes in individual patient metabolite levels grouped by survival status at last follow-up. C, Kaplan-Meier analysis illustrating 
survival over time in patients with pulmonary arterial hypertension divided into groups according to the changes in N-acetyl-
methionine levels between serial samples.
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minolysis is another alternative energy production path-
way to glucose oxidation, with the product glutamate 
entering the TCA cycle as α-ketoglutarate. Inhibition of 
glutaminolysis and restoration of glucose oxidation have 
beneficial effects in rat models of right ventricular hy-
pertrophy.34 Increased circulating glutamate levels have 
previously been seen in cancer patients35; however, an-
tiglutaminolysis therapeutic targets have demonstrated 
toxic side effects.36 The buildup of TCA intermediates 
and the precursors to the molecules that enter the cycle 
(acylcarnitines and glutamate) may indicate dysfunction 
of this cycle, or at least the inability to keep pace with 
the demands of the most active cells such as proliferat-
ing pulmonary vascular cells. Increased levels of citrate, 
succinate, and fatty acid metabolites have been demon-
strated in lung tissue from patients with PAH,11 suggest-
ing that dysfunctional energy metabolism is a feature of 
the diseased tissue. Restoration of glucose oxidation 
by dichloroacetate therapy is under investigation as a 
treatment for PAH (ClinicalTrials.gov. Unique identifier: 
NCT01083524),37 and maximizing the capacity of the 
TCA cycle to process the acetyl-CoA produced may be a 
complementary therapeutic approach.
Consistent with previous reports, we found a signifi-
cant increase in the circulating levels of long-chain ac-
ylcarnitines (oleoylcarnitine)38 and short-chain (myris-
toylcarnitine, acetylcarnitine, hydroxbutyrylcarnitine) 
and medium-chain (adipoylcarnitine, suberoylcarnitine) 
products. The accumulation of acylcarnitines may it-
self be detrimental, effecting cardiac electrophysi-
ological changes and arrhythmias.39 There is also 
increasing evidence that accumulation of long-chain 
acylcarnitines may contribute to insulin resistance,40 
which is itself common and associated with prognosis 
in PAH.41
Lipids, Steroids, Polyamines, and Tryptophan 
Metabolites
Multiple sphingomyelin and phosphatidylcholine lipid 
species were significantly reduced in patients with 
PAH, relating to increased mortality. Sphingomyelins 
are the most abundant subclass of sphingolipids, with 
other subclasses including sphinogosines, ceramides, 
and glycophospholipids.42 In patients with chronic ob-
structive pulmonary disease, low plasma levels of sev-
eral sphingomyelins relate to disease severity.43 As a 
membrane constituent, sphingomyelins are implicated 
in transmembrane signaling and are generated from 
phosphatidylcholine and ceramide by sphingomyelin 
synthase, the knockout of which leads to mitochondrial 
dysfunction and reduced insulin release.44 Sphingomy-
elins may also be considered a source of ceramide, 
which directly (and indirectly through other active lipid 
products) regulates cell proliferation, apoptosis, cell 
migration, and autophagy.45
Reduced lineoyl-glycerophosphocholine has been 
shown to be an early marker of insulin resistance in non-
diabetics,46 and decreased circulating levels of several 
phosphatidylcholines were seen in patients with severe 
heart failure.47 Phospholipids are also sources of mul-
tiple cellular signaling molecules, including eicosanoids 
such as prostacyclin,48 levels of which are known to be 
reduced in pulmonary hypertension, with replacement an 
established treatment option.
Circulating levels of DHEA-S and its metabolites (an-
drosterone, epiandrosterone, and androstenediol/4-
androsten-3β, 17β-diol disulfate) were reduced in 
patients with PAH compared with healthy control 
subjects, consistent with a recent report of reduced 
circulating levels of DHEA-S in a small cohort of 23 
A B
Figure 7. Circulating angiogenin levels.  
A, Plasma angiogenin levels determined by ELISA in healthy control subjects and patients with PAH. B, Scatterplot of plasma 
N2,N2-dimethylguanosine vs plasma angiogenin in control subjects and patients with pulmonary arterial hypertension (PAH). 
Statistics shown are from the Spearman rank test.
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male patients with PAH compared with healthy control 
subjects.49 Differences in DHEA-S between patients 
with PAH and control subjects were independent of the 
more subtle effects of both sex and age (Figure III in 
the online-only Data Supplement), and lower DHEA-S 
levels were independently associated with mortality. 
Treatment with DHEA or DHEA-S has repeatedly been 
shown to prevent and reverse pulmonary hypertension 
in experimental rat models,50 with clinical trials ongo-
ing in chronic obstructive pulmonary disease–associat-
ed pulmonary hypertension (ClinicalTrials.gov. Unique 
identifier: NCT00581087).
We found increased levels of a breakdown product 
of N1-acetylspermidine, acisoga. Other metabolites of 
polyamine metabolism (4-acetamidobutanoate and N-
acetylputrescine) were increased in PAH in relation to 
bilirubin levels and were prognostic in 2 distinct PAH co-
horts, independently of established prognostic markers. 
Several animal models of pulmonary hypertension have 
demonstrated evidence of increased polyamine levels 
and metabolism in lung tissue.51 Administration of mono-
crotaline to rats led to significantly increased levels of 
polyamines and the development of pulmonary hyperten-
sion and right ventricular hypertrophy, which could be 
prevented by the administration of an inhibitor of poly-
amine biosynthesis,52 suggesting that these molecules 
may be novel therapeutic targets.
In our study, we validated findings of elevated cir-
culating tryptophan metabolites14 with increased C-
glycosyltryptophan and kynurenine in patients with PAH 
compared with healthy control subjects, but changes in 
kynurenine were related to increased bilirubin levels and 
liver dysfunction. Levels of tryptophan and its other ma-
jor metabolite, serotonin, were not significantly altered 
in our analysis.
Limitations
The majority of patients included in this study were 
patients with prevalent disease on established treat-
ments. A subanalysis conducted with 40 patients with 
incident disease showed similar results. Corrections 
were also made for potential treatment effects in the 
main analyses, including PAH-specific and comorbidity-
related therapies, as well as demographics and renal/
hepatic function.
Patients and control subjects were sampled in the 
nonfasting state, and information on insulin resistance 
was not available for all participants. Patients were also 
sampled from a peripheral vein. The stronger perfor-
mance of discriminating models in discovery analyses 
suggests that optimization could further improve their 
performance in distinct cohorts. Strongly correlated 
metabolites would not have been selected in the dis-
criminant modeling, so each metabolite used in the final 
models may represent clusters of multiple metabolites. 
Evidence of tissue specificity and the source of circu-
lating metabolites in pulmonary hypertension require 
further studies, for example, by transpulmonary sam-
pling and direct measurements from tissue samples, to 
better localize the source of informative metabolites. 
Plasma levels of metabolites may not reflect levels in 
the most important tissues; for example, increased bile 
acid metabolites have been demonstrated in PAH lung 
tissue,53 but no differences were seen in circulating lev-
els in our study.
Summary and Conclusions
Increased circulating modified nucleosides (N2,N2-
dimethylguanosine, N1-methylinosine), TCA cycle inter-
mediates (malate, fumarate), glutamate, fatty acid ac-
ylcarnitines, and polyamine metabolites and decreased 
levels of steroids, sphingomyelins, and phosphatidyl-
cholines are characteristics of patients with PAH that 
distinguish them from symptomatic patients without 
pulmonary hypertension. Improvements in circulating 
metabolite levels are associated with a better progno-
sis and could be used to monitor response to PAH treat-
ments. Indeed, our results support the investigation of 
therapeutic strategies targeted at alterations in energy 
metabolism in PAH and suggest options for correcting 
translational regulation that also merit further study.
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Metabolomic profiling methodology 
Samples were prepared with use of an automated MicroLab STAR system (Hamilton 
Company, Reno, NV, USA). For quality control (QC), a pooled sample from all experimental 
samples was used throughout the experiment, and a mixture of Metabolon QC standards were 
spiked into all experimental samples to monitor instrument performance and chromatographic 
alignment.  Samples were randomised prior to experimentation.  
 
Experiments were conducted on Waters Acuity ultra-performance liquid chromatography 
(UPLC) systems (Waters Corporation, Milford, MA, USA) using Thermo Scientific Q-
Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray 
 
Supplementary Materials 
ionization (HESI-II) source and Orbitrap mass analyser (Thermo Fisher Scientific, MA, 
USA).  
 
The analysis platform used four methods for Ultrahigh Performance Liquid Chromatography-
Tandem Mass Spectroscopy (UPLC-MS/MS) including a) positive ion mode electrospray 
ionisation (ESI), b) positive ion mode optimised for hydrophobic compounds, c) negative ion 
mode ESI and d) negative ionisation following elution from a hydrophilic interaction 
chromatography (HILIC) column. Scan time varied between methods and covered 70-
1000m/z.   
 
The resulting spectra were compared to the in-house Metabolon standard library using 
retention time, mass (m/z), adducts and MS/MS spectra. Analysis using this platform has 
been applied to measure metabolite levels in human plasma in control 1, 2 and disease 
populations 3, 4. All experiments and runs were conducted on the same day.    
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Table S1 (below). Metabolites distinguishing pulmonary arterial hypertension (PAH) from healthy (HC) and disease controls (DC). 97 metabolites 
that are significantly different between PAH and healthy controls in 3 cohorts (p<7.3e-5) are shown. Mean values are given and the data is scaled to the 
healthy control group. Significance from linear regression is shown (p value), and for metabolites with p>0.05 in PAH HC linear regression, the significant 
confounder is shown. Significance is also shown for Mann Whitney U test between PAH treatment naïve patients versus all HC, and PAH bone 
morphogenetic protein type 2 receptor (BMPR2) mutation carriers versus patients with no BMPR2 mutation. GPC, glycerophosphocholine. *probable 
metabolite identity, but unconfirmed (see methods).  
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  Group averages (z-score relative to healthy control levels) Statistics (p-values) and major confounders 
Metabolite Metabolic Pathway Discovery Validation1 Validation2 PAH BMPR2 Linear Regression Confounder Sub-analyses 
  HC DC 
PAH            
(19-70) 
HC DC PAH PAH2 Naïve Mutation 
HC vs               
PAH 
HC+DC 
vs            
PAH 
HC vs                        
PAH 
PAH 
Naïve 
vs HC 
BMPR2 
vs PAH 
Increased in PAH vs HC and DC (independent of confounders) 
N-acetylaspartate (NAA) Alanine & Aspartate  0.12 0.21 1.13 -0.11 0.64 1.32 0.87 1.47 0.93 2.3E-04 4.6E-03  3.0E-09 0.46 
octadecanedioate 
Fatty Acid, 
Dicarboxylate 
0.07 0.12 0.82 -0.07 0.34 0.93 0.35 0.95 0.43 1.5E-02 1.3E-02  7.3E-06 0.25 
3-hydroxy-3-methylglutarate Mevalonate  -0.07 0.57 0.89 0.07 0.57 1.15 0.76 1.20 0.75 3.5E-02 3.0E-02  1.6E-09 0.12 
acisoga Polyamine  -0.10 1.07 1.42 0.09 1.14 1.95 1.22 1.93 1.04 1.9E-04 1.5E-02  2.7E-11 2.9E-02 
N1-methylinosine 
Purine, Hypo- 
Xanthine/Inosine  
-0.22 0.58 1.50 0.20 0.86 1.85 1.29 1.78 1.50 8.1E-04 2.2E-02  1.5E-13 0.48 
xanthine 
Purine, Hypo- 
Xanthine/Inosine  
0.11 0.56 0.98 -0.10 0.62 1.06 1.00 1.35 1.16 2.0E-07 2.8E-03  3.4E-09 0.19 
N2,N2-dimethylguanosine Purine, Guanine  -0.11 0.83 1.56 0.10 1.15 2.00 1.39 1.95 1.36 1.1E-02 3.9E-02  2.2E-13 0.11 
3-ureidopropionate Pyrimidine, Uracil  -0.14 0.22 0.62 0.13 0.09 1.16 0.54 1.16 0.47 1.7E-02 9.0E-04  4.0E-09 0.36 
malate TCA Cycle -0.18 0.60 1.17 0.17 0.69 1.64 1.02 1.81 1.11 8.8E-04 9.1E-03  1.5E-14 0.35 
X - 12688 Unknown -0.11 1.01 1.50 0.10 1.14 1.70 1.26 1.76 0.99 4.9E-05 3.2E-02  6.4E-13 1.6E-02 
X - 13737 Unknown -0.05 0.19 0.97 0.05 0.38 1.03 0.91 1.15 0.94 1.8E-02 6.1E-03  1.9E-08 0.70 
X - 21796 Unknown 0.07 0.19 0.96 -0.07 0.44 1.06 0.73 1.33 0.83 5.0E-03 1.3E-02  1.9E-12 0.83 
Decreased in PAH vs HC and DC (independent of confounders)                         
palmitoylcholine 
Fatty Acid  (Acyl 
Choline) 
-0.05 -0.14 -1.33 0.05 -0.35 -0.73 -1.10 -0.94 -1.35 1.7E-03 8.3E-03  3.9E-05 4.8E-02 
1-arachidonoyl-GPC 
(20:4n6)* 
Lysolipid -0.08 -0.14 -1.09 0.08 -0.25 -0.74 -0.81 -0.81 -1.00 1.2E-02 3.2E-02  5.9E-05 0.27 
1-docosapentaenoyl-GPC 
(22:5n3)* 
Lysolipid -0.03 -0.17 -1.03 0.03 -0.21 -0.80 -0.84 -0.79 -1.02 9.0E-03 6.7E-03  1.6E-05 0.23 
1-linoleoyl-2-
eicosapentaenoyl-GPC 
(18:2/20:5)* 
Phospholipid  0.03 -0.39 -0.81 -0.03 -0.13 -1.13 -0.81 -1.16 -0.77 2.4E-02 1.2E-02  3.4E-08 0.68 
sphingomyelin (d18:1/20:0, 
d16:1/22:0)* 
Sphingolipid  0.05 -0.43 -1.02 -0.05 -0.38 -1.09 -1.05 -1.24 -0.93 1.3E-02 7.7E-03  1.2E-08 0.49 
sphingomyelin (d18:1/21:0, 
d17:1/22:0, d16:1/23:0)* 
Sphingolipid  0.03 -0.44 -0.89 -0.03 -0.32 -0.93 -0.76 -1.04 -0.83 2.7E-03 4.0E-02  1.4E-08 0.78 
sphingomyelin (d18:1/22:1, 
d18:2/22:0, d16:1/24:1)* 
Sphingolipid  0.07 -0.37 -1.09 -0.06 -0.32 -1.16 -1.03 -1.21 -1.12 2.6E-03 7.2E-04  1.8E-07 0.95 
sphingomyelin (d18:2/23:0, 
d18:1/23:1, d17:1/24:1)* 
Sphingolipid  0.04 -0.27 -0.63 -0.04 -0.17 -0.60 -0.54 -0.68 -0.66 4.9E-04 4.4E-02  1.0E-06 0.40 
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Increased in PAH vs HC (independent of confounders)                           
oleoyl ethanolamide Endocannabinoid 0.10 1.02 0.88 -0.09 1.15 1.02 0.52 0.84 0.29 1.3E-03 2.2E-01  5.6E-05 5.4E-03 
3-hydroxybutyrylcarnitine 
(1) 
Fatty Acid (Acyl 
Carnitine) 
0.02 0.52 0.91 -0.01 0.81 0.97 0.60 1.11 0.62 6.1E-05 1.1E-01  7.3E-09 4.5E-02 
3-hydroxybutyrylcarnitine 
(2) 
Fatty Acid (Acyl 
Carnitine) 
0.07 0.76 1.26 -0.06 1.02 1.24 0.90 1.49 0.81 4.7E-03 6.8E-01  3.4E-09 3.8E-02 
acetylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
0.11 0.43 1.02 -0.10 0.77 0.88 0.59 0.94 0.56 1.2E-02 2.9E-01  5.7E-06 3.1E-02 
adipoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
-0.04 0.41 1.44 0.04 0.94 1.69 1.25 1.77 1.20 4.6E-02 3.9E-01  5.8E-10 0.09 
myristoleoylcarnitine* 
Fatty Acid (Acyl 
Carnitine) 
0.04 0.33 0.75 -0.04 0.64 0.85 0.53 0.91 0.37 1.6E-02 4.6E-01  6.2E-05 1.0E-02 
myristoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
0.01 0.46 0.81 -0.01 0.87 1.06 0.60 1.07 0.44 4.1E-02 9.5E-01  9.4E-06 1.1E-02 
oleoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
0.03 0.53 0.96 -0.03 0.83 1.39 1.20 1.22 0.87 1.8E-02 6.7E-01  3.2E-07 0.10 
palmitoleoylcarnitine* 
Fatty Acid (Acyl 
Carnitine) 
0.08 0.56 0.91 -0.07 0.90 1.23 0.85 1.14 0.69 8.5E-03 8.9E-01  7.9E-07 4.1E-02 
suberoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
0.10 0.55 1.40 -0.09 0.98 1.61 1.23 1.66 1.03 7.1E-03 3.5E-01  1.3E-09 2.9E-02 
glutamate Glutamate  0.16 0.47 1.13 -0.14 0.41 0.98 0.71 1.12 0.83 2.9E-02 1.4E-01  2.7E-07 0.98 
methionine sulfone 
Met, Cys, SAM & 
Tau 
-0.03 0.49 1.57 0.03 0.98 1.79 1.40 1.56 1.29 3.6E-02 4.9E-01  1.8E-09 0.14 
N-acetylmethionine 
Met, Cys, SAM & 
Tau 
-0.04 0.48 1.08 0.04 0.63 1.27 0.60 1.30 0.80 3.3E-03 1.6E-01  1.3E-09 0.22 
N-acetyltaurine 
Met, Cys, SAM & 
Tau 
0.07 0.56 1.02 -0.06 0.71 1.15 0.63 1.15 0.37 1.0E-03 7.1E-02  2.7E-07 9.7E-04 
N-formylmethionine 
Met, Cys, SAM & 
Tau 
-0.17 0.49 1.08 0.16 0.69 1.53 0.78 1.59 0.85 4.8E-02 3.0E-01  5.8E-10 0.10 
5,6-dihydrothymine 
Pyrimidine, 
Thymine  
-0.22 0.65 1.33 0.20 0.96 1.37 0.62 1.38 0.71 2.0E-04 6.7E-02  1.2E-08 0.15 
alpha-ketoglutarate TCA Cycle -0.04 0.45 0.68 0.04 0.71 1.57 1.13 1.61 1.14 2.2E-02 2.4E-01  2.6E-13 1.00 
fumarate TCA Cycle -0.15 0.30 0.65 0.13 0.45 1.14 0.56 1.23 0.31 2.1E-02 9.8E-02  3.5E-16 0.28 
C-glycosyltryptophan Tryptophan  -0.05 0.55 1.11 0.05 0.84 1.37 0.76 1.30 0.59 4.8E-02 3.9E-01  5.9E-07 4.7E-03 
X - 12127 Unknown 0.06 0.63 0.85 -0.06 0.61 1.05 0.67 1.07 0.73 1.6E-02 4.4E-01  1.6E-08 0.53 
X - 12472 Unknown -0.04 0.71 1.03 0.04 0.82 1.05 0.96 1.15 0.93 3.4E-03 8.2E-01  2.5E-07 0.59 
X - 12739 Unknown -0.09 0.87 1.02 0.08 1.11 1.12 0.99 1.18 0.97 2.4E-02 1.8E-01  6.8E-07 0.35 
X - 12824 Unknown -0.02 0.54 0.85 0.02 0.74 1.08 0.79 1.16 0.78 2.0E-02 6.8E-01  9.5E-08 0.44 
X - 17327 Unknown 0.03 0.66 0.86 -0.03 0.81 0.97 0.82 1.02 0.78 2.6E-02 7.0E-01  2.4E-06 0.34 
X - 21829 Unknown -0.07 0.44 0.82 0.06 0.65 1.24 0.66 1.41 0.62 2.5E-02 5.6E-01  2.4E-10 0.10 
X - 24307 Unknown 0.04 0.68 0.70 -0.04 0.52 1.18 0.97 1.09 0.94 6.9E-05 7.2E-02  1.2E-07 0.88 
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X - 24513 Unknown -0.10 0.67 1.05 0.09 0.92 1.44 0.98 1.30 0.77 2.4E-02 4.8E-01  1.4E-07 9.1E-03 
X - 24527 Unknown -0.08 0.86 1.11 0.08 1.17 1.22 1.06 1.22 0.94 3.5E-02 1.9E-01  2.2E-06 0.25 
X - 24678 Unknown 0.21 0.74 1.20 -0.19 0.62 1.34 0.70 1.33 0.83 4.9E-03 1.2E-01  3.6E-11 0.42 
X - 24766 Unknown -0.31 0.45 0.82 0.28 0.60 1.07 0.85 0.89 0.92 1.9E-02 3.9E-01  5.1E-07 0.78 
Decreased in PAH vs HC (independent of confounders)                           
asparagine Alanine & Aspartate  -0.06 -0.58 -0.88 0.05 -0.55 -1.00 -0.90 -1.22 -0.95 8.7E-04 8.5E-02  2.3E-07 0.64 
dehydroisoandrosterone 
sulfate (DHEA-S) 
Steroid -0.05 -1.17 -1.53 0.04 -0.95 -1.74 -1.77 -1.53 -1.56 2.5E-02 4.1E-01  1.3E-09 0.46 
X - 23765 Unknown 0.09 -0.50 -0.72 -0.08 -0.50 -0.90 -0.90 -1.02 -1.08 8.1E-04 2.0E-01  9.7E-07 0.15 
Increased in PAH vs HC                           
N-acetylalanine Alanine & Aspartate  -0.11 0.55 0.76 0.10 0.88 1.15 0.66 1.04 0.50 9.9E-01 2.3E-01 Diuretics 3.2E-05 1.6E-02 
N-acetylneuraminate Aminosugar  -0.11 0.50 0.93 0.11 0.63 0.88 0.47 0.76 0.28 7.4E-02 2.4E-01 Age 1.8E-04 1.0E-03 
erythronate* Aminosugar  -0.11 0.45 0.71 0.10 0.68 1.16 0.59 1.10 0.37 7.1E-01 6.5E-01 Bilirubin 5.4E-06 6.0E-03 
N-acetylglucosamine/N-
acetylgalactosamine 
Aminosugar  -0.14 0.50 0.72 0.13 0.89 0.95 0.58 0.62 0.54 1.0E-01 7.3E-01 Gender 1.8E-03 4.4E-02 
gulonic acid* 
Ascorbate & 
Aldarate  
-0.08 0.49 0.61 0.07 0.57 0.79 0.61 0.81 0.47 8.5E-01 5.3E-01 Age 4.5E-05 2.8E-02 
palmitoylcarnitine 
Fatty Acid (Acyl 
Carnitine) 
-0.03 0.49 0.91 0.03 1.03 1.28 0.95 1.23 0.90 6.0E-02 9.2E-01 Bilirubin 1.6E-07 0.43 
malonylcarnitine Fatty Acid Synthesis 0.00 0.20 0.56 0.00 0.29 0.94 0.48 0.96 0.57 1.3E-01 3.8E-02 Bilirubin 3.8E-09 0.53 
N-acetylserine 
Glycine, Serine & 
Threonine  
-0.16 0.63 1.00 0.15 1.04 1.49 0.97 1.38 0.85 5.2E-01 4.0E-01 Bilirubin 6.9E-08 0.05 
N-acetylthreonine 
Glycine, Serine & 
Threonine  
-0.22 0.31 0.68 0.20 0.64 0.99 0.55 1.10 0.47 6.5E-01 9.7E-01 Bilirubin 4.4E-07 2.0E-02 
1-methylimidazoleacetate Histidine  -0.05 0.52 0.86 0.04 0.50 1.32 0.86 1.02 0.74 6.0E-02 9.5E-02 Age 7.9E-07 0.08 
imidazole propionate Histidine  -0.21 0.44 0.84 0.19 0.71 0.99 0.79 0.98 0.84 1.4E-01 8.1E-01 Bilirubin 1.1E-07 0.54 
quinolinate 
Nicotinate & 
Nicotinamide  
-0.11 0.46 0.76 0.10 0.68 1.19 0.86 0.95 0.58 6.0E-01 5.0E-01 Bilirubin 1.8E-04 3.8E-02 
vanillylmandelate (VMA) 
Phenylalanine & 
Tyrosine  
-0.21 0.35 1.00 0.19 0.37 1.52 0.83 1.75 0.96 2.3E-01 1.5E-02 Age 6.3E-12 0.37 
4-acetamidobutanoate Polyamine  -0.10 0.72 1.22 0.09 0.90 1.93 1.26 1.83 1.19 8.6E-01 7.0E-01 Bilirubin 1.0E-11 0.15 
N-acetylputrescine Polyamine  -0.16 0.66 0.84 0.15 0.72 1.32 0.66 0.93 0.53 5.8E-01 6.2E-01 Bilirubin 3.0E-06 3.8E-02 
N6-carbamoylthreonyl 
adenosine 
Purine, Adenine  -0.12 0.58 1.04 0.11 0.90 1.49 1.06 1.31 0.92 1.7E-01 4.5E-01 Age 8.4E-09 4.6E-02 
N1-methyladenosine Purine, Adenine  -0.21 0.70 0.94 0.19 0.91 1.26 0.65 1.03 0.46 8.6E-01 1.4E-01 Bilirubin 2.4E-05 4.4E-03 
N6-succinyladenosine Purine, Adenine  -0.06 0.38 0.63 0.05 0.43 0.86 0.50 0.94 0.44 1.5E-01 2.7E-01 Bilirubin 1.2E-09 2.7E-03 
N4-acetylcytidine 
Pyrimidine, 
Cytidine  
0.07 0.55 1.31 -0.06 0.77 1.50 1.22 1.33 1.19 2.7E-01 6.7E-01 Bilirubin 1.3E-08 0.47 
orotidine Pyrimidine, Orotate  -0.11 0.58 1.07 0.10 0.95 1.27 0.96 1.27 0.83 2.8E-01 5.3E-01 Bilirubin 1.4E-08 0.08 
pseudouridine Pyrimidine, Uracil  -0.08 0.77 1.22 0.08 1.05 1.66 1.17 1.68 0.97 1.5E-01 8.6E-01 Bilirubin 5.2E-11 1.4E-02 
 
Supplementary Materials 
kynurenine Tryptophan  -0.14 0.29 1.00 0.13 0.57 1.37 0.77 1.44 0.68 5.6E-01 3.3E-01 Bilirubin 1.2E-08 0.07 
X - 12100 Unknown -0.13 0.49 1.04 0.12 0.85 1.26 0.88 1.28 0.75 1.3E-01 4.6E-01 Age 9.8E-08 0.06 
X - 11564 Unknown -0.13 0.51 0.94 0.12 0.90 1.48 0.83 1.43 0.73 9.6E-01 8.8E-01 Bilirubin 3.5E-07 0.06 
X - 12026 Unknown -0.16 0.69 1.58 0.14 1.01 2.01 1.36 2.20 1.26 6.9E-01 7.7E-01 Bilirubin 3.8E-12 0.07 
X - 12117 Unknown -0.12 0.66 1.18 0.11 0.98 1.55 1.35 1.50 1.20 6.7E-01 3.6E-01 Bilirubin 7.7E-09 0.19 
X - 15503 Unknown -0.17 0.28 1.04 0.15 0.70 1.64 1.06 1.68 1.33 6.3E-01 5.6E-02 Bilirubin 2.5E-10 0.63 
X - 11429 Unknown -0.07 0.88 1.52 0.07 1.31 1.98 1.45 1.88 1.18 9.1E-02 8.4E-01 Diuretics 3.4E-10 2.0E-02 
X - 21736 Unknown -0.06 0.33 1.04 0.06 0.59 1.46 0.92 1.57 0.95 2.7E-01 3.5E-01 Diuretics 1.1E-10 0.42 
pro-hydroxy-pro 
Urea cycle; 
Arginine & Proline  
-0.03 0.32 0.87 0.03 0.51 1.24 0.90 1.07 0.98 9.6E-01 6.9E-01 Diuretics 2.9E-06 0.95 
Decreased in PAH vs HC                         
histidine Histidine  -0.07 -0.74 -1.57 0.06 -0.91 -1.89 -1.71 -1.78 -1.60 6.1E-02 8.2E-03 Prostanoids 1.2E-11 4.2E-01 
1-linoleoyl-GPC (18:2) Lysolipid -0.10 -0.59 -1.22 0.09 -0.51 -1.14 -1.12 -1.33 -1.10 5.8E-02 2.4E-02 Bilirubin 1.3E-07 5.2E-01 
2-linoleoyl-GPC (18:2)* Lysolipid -0.11 -0.55 -1.23 0.10 -0.42 -0.97 -1.09 -1.35 -1.15 9.4E-02 2.9E-02 Bilirubin 4.5E-08 9.6E-01 
1-dihomo-linoleoyl-GPC 
(20:2)* 
Lysolipid 0.00 -0.39 -0.95 0.00 -0.49 -0.86 -1.14 -0.98 -1.30 2.4E-01 4.3E-01 Statins 5.5E-05 1.2E-01 
1-(1-enyl-palmitoyl)-2-
linoleoyl-GPC (P-
16:0/18:2)* 
Plasmalogen 0.01 -0.38 -1.06 -0.01 -0.17 -1.13 -0.98 -1.28 -1.08 2.3E-01 1.5E-01 PDE5 inhib 5.1E-08 9.4E-01 
behenoyl sphingomyelin 
(d18:1/22:0)* 
Sphingolipid  0.02 -0.22 -0.75 -0.01 -0.20 -0.71 -0.92 -0.78 -0.77 1.4E-01 3.0E-02 Gender 3.6E-06 8.4E-01 
4-androsten-3beta,17beta-
diol disulfate (1) 
Steroid -0.04 -0.64 -0.87 0.03 -0.47 -0.81 -1.14 -0.55 -1.06 2.4E-01 5.4E-01 Gender 4.0E-03 6.8E-01 
4-androsten-3beta,17beta-
diol monosulfate (1) 
Steroid -0.01 -0.85 -1.15 0.01 -0.68 -1.30 -1.40 -1.18 -1.32 5.6E-02 3.7E-01 Gender 5.8E-07 9.3E-01 
androsterone sulfate Steroid -0.02 -0.70 -1.33 0.02 -0.69 -1.40 -1.40 -1.14 -1.33 1.5E-01 2.0E-01 Gender 4.6E-06 7.3E-01 
epiandrosterone sulfate Steroid -0.02 -0.86 -1.42 0.01 -0.72 -1.50 -1.49 -1.23 -1.40 1.3E-01 3.9E-01 Gender 1.1E-06 6.4E-01 
pregn steroid monosulfate* Steroid -0.08 -0.83 -0.88 0.07 -0.68 -0.93 -1.04 -0.71 -0.84 1.0E-01 6.7E-01 Gender 3.3E-04 2.6E-01 
X - 23749 Unknown 0.04 -0.16 -1.10 -0.03 -0.34 -1.05 -1.12 -0.94 -1.41 2.0E-01 2.7E-01 BMI 5.4E-05 0.02 
arginine 
Urea cycle; 
Arginine & Proline  
-0.05 -0.67 -1.05 0.04 -0.79 -1.40 -1.47 -1.80 -1.32 1.1E-01 3.1E-01 DM drugs 2.1E-11 6.5E-01 
homoarginine 
Urea cycle; 
Arginine & Proline  
-0.05 -0.70 -0.91 0.05 -0.59 -1.13 -1.06 -1.11 -0.86 5.1E-02 2.1E-01 Ethnicity 4.8E-07 7.6E-02 
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Table S1. Metabolites distinguishing pulmonary arterial hypertension (PAH) from healthy (HC) and disease controls (DC). 97 metabolites that are 
significantly different between PAH and healthy controls in 3 cohorts (p<7.3e-5) are shown. Mean values are given and the data is scaled to the healthy 
control group. Significance from linear regression is shown (p value), and for metabolites with p>0.05 in PAH HC linear regression, the significant 
confounder is shown. Significance is also shown for Mann Whitney U test between PAH treatment naïve patients versus all HC, and PAH bone 
morphogenetic protein type 2 receptor (BMPR2) mutation carriers versus patients with no BMPR2 mutation. GPC, glycerophosphocholine. *probable 
metabolite identity, but unconfirmed (see methods).  
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Table S2. (below) Survival analysis. 
Metabolite Metabolic Pathway Discovery  Validation1 
   Hazard Ratio  Sig Hazard Ratio Sig 
Higher value indicates mortality. Independent of established prognostic markers 
N-acetylalanine Alanine and Aspartate  2.02 (1.22-3.36) 6.43E-03 2.08 (1.12-3.86) 2.04E-02 
pimeloylcarnitine/3-methyladipoylcarnitine Fatty Acid (Acyl Carnitine) 2.16 (1.28-3.66) 4.03E-03 2.52 (1.24-5.10) 1.04E-02 
1-methylimidazoleacetate Histidine  2.26 (1.37-3.73) 1.43E-03 1.74 (1.03-2.93) 3.93E-02 
N-acetylmethionine Methionine, Cysteine, SAM and Taurine  2.36 (1.41-3.96) 1.16E-03 2.29 (1.18-4.43) 1.44E-02 
N-formylmethionine Methionine, Cysteine, SAM and Taurine  1.79 (1.20-2.68) 4.50E-03 1.98 (1.20-3.25) 7.15E-03 
4-acetamidobutanoate Polyamine  2.20 (1.45-3.35) 2.19E-04 2.02 (1.30-3.14) 1.83E-03 
N-acetylputrescine Polyamine  1.74 (1.04-2.91) 3.54E-02 2.92 (1.51-5.66) 1.50E-03 
N1-methylinosine Purine , (Hypo)Xanthine/Inosine  2.82 (1.74-4.57) 2.42E-05 1.73 (1.09-2.77) 2.11E-02 
urate Purine , (Hypo)Xanthine/Inosine  1.61 (1.06-2.42) 2.43E-02 2.14 (1.26-3.64) 4.73E-03 
N6-succinyladenosine Purine , Adenine  3.89 (1.40-10.82) 9.18E-03 8.31 (1.94-35.54) 4.29E-03 
N6-carbamoylthreonyladenosine Purine , Adenine  3.10 (1.60-6.00) 8.04E-04 2.08 (1.08-4.00) 2.81E-02 
N1-methyladenosine Purine , Adenine  1.94 (1.25-3.01) 2.92E-03 1.93 (1.12-3.32) 1.75E-02 
N2,N2-dimethylguanosine Purine , Guanine  2.53 (1.57-4.08) 1.35E-04 1.86 (1.14-3.03) 1.25E-02 
pseudouridine Pyrimidine , Uracil  1.78 (1.07-2.94) 2.54E-02 2.75 (1.48-5.12) 1.45E-03 
X - 24020 Unknown 2.47 (1.42-4.30) 1.36E-03 1.84 (1.00-3.39) 4.94E-02 
X - 24513 Unknown 2.34 (1.28-4.29) 5.92E-03 2.18 (1.11-4.29) 2.34E-02 
X - 12472 Unknown 2.24 (1.44-3.47) 3.11E-04 1.57 (1.00-2.46) 4.97E-02 
X - 12739 Unknown 2.07 (1.41-3.04) 2.07E-04 1.56 (1.06-2.28) 2.28E-02 
X - 24527 Unknown 1.85 (1.38-2.48) 4.09E-05 1.43 (1.03-1.99) 3.12E-02 
X - 12688 Unknown 1.81 (1.23-2.68) 2.83E-03 2.02 (1.27-3.19) 2.80E-03 
X - 24728 Unknown 1.70 (1.09-2.64) 1.96E-02 2.04 (1.09-3.79) 2.50E-02 
X - 15503 Unknown 1.67 (1.11-2.52) 1.38E-02 1.51 (1.03-2.22) 3.48E-02 
X - 11564 Unknown 1.62 (1.10-2.38) 1.49E-02 1.60 (1.03-2.47) 3.51E-02 
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X - 24411 Unknown 1.54 (1.04-2.27) 3.05E-02 2.16 (1.32-3.54) 2.17E-03 
X - 11429 Unknown 1.47 (1.05-2.06) 2.65E-02 1.79 (1.18-2.71) 5.76E-03 
Lower value indicates mortality. Independent of established prognostic markers 
1-eicosapentaenoyl-GPE (20:5)* Lysolipid 0.60 (0.43-0.84) 2.65E-03 0.62 (0.39-1.00) 4.98E-02 
1-eicosapentaenoyl-GPC (20:5)* Lysolipid 0.47 (0.31-0.73) 6.30E-04 0.50 (0.31-0.82) 6.05E-03 
1-linoleoyl-2-docosahexaenoyl-GPC (18:2/22:6)* Phospholipid  0.64 (0.46-0.89) 7.40E-03 0.65 (0.47-0.91) 1.27E-02 
1-oleoyl-2-docosapentaenoyl-GPC (18:1/22:5n6)* Phospholipid  0.64 (0.47-0.87) 4.11E-03 0.62 (0.43-0.90) 1.06E-02 
1-myristoyl-2-arachidonoyl-GPC (14:0/20:4)* Phospholipid  0.57 (0.39-0.83) 3.68E-03 0.68 (0.48-0.96) 2.66E-02 
phosphatidylcholine (18:0/20:5, 16:0/22:5n6)* Phospholipid  0.54 (0.37-0.77) 7.30E-04 0.42 (0.25-0.72) 1.44E-03 
1-palmitoyl-2-eicosapentaenoyl-GPC (16:0/20:5)* Phospholipid  0.53 (0.37-0.75) 4.11E-04 0.43 (0.26-0.74) 1.96E-03 
1-linoleoyl-2-eicosapentaenoyl-GPC (18:2/20:5)* Phospholipid  0.48 (0.33-0.70) 1.38E-04 0.60 (0.41-0.88) 8.59E-03 
1-myristoyl-2-docosahexaenoyl-GPC (14:0/22:6)* Phospholipid  0.47 (0.31-0.72) 4.84E-04 0.49 (0.29-0.81) 5.62E-03 
dehydroisoandrosterone sulfate (DHEA-S) Steroid 0.71 (0.52-0.97) 3.19E-02 0.55 (0.33-0.91) 2.06E-02 
X - 24041 Unknown 0.46 (0.29-0.72) 6.88E-04 0.61 (0.38-0.99) 4.45E-02 
Higher value indicates mortality 
hexadecanedioate Fatty Acid, Dicarboxylate 1.53 (1.09-2.14) 1.40E-02 1.67 (1.16-2.41) 5.58E-03 
N-acetyltaurine Methionine, Cysteine, SAM and Taurine  1.97 (1.16-3.35) 1.19E-02 2.24 (1.13-4.43) 2.05E-02 
3-hydroxy-3-methylglutarate Mevalonate  1.68 (1.03-2.74) 3.78E-02 2.08 (1.02-4.23) 4.40E-02 
vanillylmandelate (VMA) Phenylalanine and Tyrosine  1.48 (1.06-2.06) 2.02E-02 1.58 (1.06-2.34) 2.38E-02 
N-acetyl-beta-alanine Pyrimidine , Uracil  1.54 (1.08-2.21) 1.80E-02 1.65 (1.18-2.32) 3.65E-03 
fumarate TCA Cycle 1.70 (1.00-2.88) 4.97E-02 2.57 (1.09-6.06) 3.09E-02 
N2,N5-diacetylornithine Urea cycle; Arginine and Proline  2.15 (1.27-3.63) 4.37E-03 2.15 (1.13-4.09) 1.95E-02 
Lower value indicates mortality 
valine Leucine, Isoleucine and Valine  0.66 (0.49-0.89) 6.80E-03 0.68 (0.48-0.95) 2.21E-02 
1-docosahexaenoyl-GPE (22:6)* Lysolipid 0.68 (0.49-0.94) 1.86E-02 0.54 (0.34-0.85) 8.27E-03 
1-dihomo-linolenoyl-GPC (20:3n3 or 6)* Lysolipid 0.57 (0.41-0.79) 7.43E-04 0.71 (0.53-0.96) 2.82E-02 
1-docosahexaenoyl-GPC (22:6)* Lysolipid 0.54 (0.35-0.81) 3.17E-03 0.57 (0.35-0.93) 2.32E-02 
phosphatidylcholine (16:0/22:5n3, 18:1/20:4)* Phospholipid  0.68 (0.48-0.96) 2.64E-02 0.59 (0.36-0.98) 4.16E-02 
1-stearoyl-2-docosahexaenoyl-GPE (18:0/22:6)* Phospholipid  0.64 (0.47-0.88) 5.99E-03 0.52 (0.32-0.85) 8.73E-03 
1-palmitoleoyl-2-docosahexaenoyl-GPC (16:1/22:6)* Phospholipid  0.62 (0.43-0.90) 1.09E-02 0.50 (0.28-0.88) 1.67E-02 
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1-pentadecanoyl-2-docosahexaenoyl-GPC (15:0/22:6)* Phospholipid  0.62 (0.42-0.90) 1.30E-02 0.34 (0.17-0.68) 1.96E-03 
1-stearoyl-2-docosahexaenoyl-GPC (18:0/22:6) Phospholipid  0.60 (0.42-0.87) 7.16E-03 0.45 (0.27-0.76) 2.76E-03 
1-stearoyl-2-docosapentaenoyl-GPC (18:0/22:5n3)* Phospholipid  0.58 (0.41-0.82) 2.11E-03 0.50 (0.30-0.83) 8.18E-03 
1-palmitoyl-2-dihomo-linolenoyl-GPC (16:0/20:3n3 or 6)* Phospholipid  0.58 (0.38-0.88) 9.67E-03 0.54 (0.35-0.84) 6.47E-03 
1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPC (P-18:0/22:6)* Plasmalogen 0.56 (0.37-0.85) 6.20E-03 0.57 (0.33-0.98) 4.06E-02 
1-(1-enyl-stearoyl)-2-docosahexaenoyl-GPE (P-18:0/22:6)* Plasmalogen 0.55 (0.37-0.82) 3.45E-03 0.49 (0.27-0.91) 2.31E-02 
1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPC (P-16:0/22:6)* Plasmalogen 0.54 (0.37-0.79) 1.31E-03 0.53 (0.32-0.87) 1.30E-02 
1-(1-enyl-palmitoyl)-2-docosahexaenoyl-GPE (P-16:0/22:6)* Plasmalogen 0.49 (0.34-0.71) 1.63E-04 0.47 (0.26-0.82) 8.30E-03 
sphingomyelin (d18:2/14:0, d18:1/14:1)* Sphingolipid  0.73 (0.53-1.00) 4.83E-02 0.48 (0.30-0.77) 2.36E-03 
sphingomyelin (d18:1/20:0, d16:1/22:0)* Sphingolipid  0.60 (0.41-0.87) 6.60E-03 0.57 (0.35-0.93) 2.32E-02 
sphingomyelin (d18:1/22:1, d18:2/22:0, d16:1/24:1)* Sphingolipid  0.59 (0.42-0.83) 2.51E-03 0.53 (0.33-0.85) 7.63E-03 
behenoyl sphingomyelin (d18:1/22:0)* Sphingolipid  0.42 (0.27-0.64) 5.94E-05 0.47 (0.27-0.82) 7.42E-03 
 
Table S2. Survival analysis in PAH. 62 metabolites significantly different between PAH survivors and non-survivors in discovery and validation1 cohorts 
(p<0.05) are shown. Hazard ratio and significance (Sig) is shown from Cox regression analysis. Hazard ratios shown are for 1 standard deviation change in 
each metabolite for ease of comparison. Metabolites which are also independent of established prognostic markers in the discovery cohort are also shown. 
*probable metabolite identity, but unconfirmed (see methods). GPC, glycerophosphocholine; GPE, glycerophosphoethanolamine. 
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Pathway Result Metabolite 
HC v 
PAH 
Prog- 
nosis 
Fatty Acid 
Metabolism(Acyl 
Carnitine) 
4.5E-05 3-hydroxybutyrylcarnitine (1) 6E-05 0.3499 
 
pimeloylcarnitine/3-
methyladipoylcarnitine NA 0.0006 
 suberoylcarnitine 0.0071 0.0044 
 3-hydroxybutyrylcarnitine (2) 0.0047 0.0046 
 palmitoleoylcarnitine* 0.0085 0.3042 
 adipoylcarnitine 0.0464 0.0106 
 acetylcarnitine 0.0118 0.141 
 myristoleoylcarnitine* 0.0165 0.6142 
 oleoylcarnitine 0.0176 0.0598 
 myristoylcarnitine 0.0412 0.2631 
 palmitoylcarnitine 0.0604 0.1959 
 linoleoylcarnitine* NA 0.0615 
 hexanoylcarnitine NA 0.5981 
 stearoylcarnitine NA 0.6611 
 octanoylcarnitine NA 0.8074 
 laurylcarnitine NA 0.8641 
 decanoylcarnitine NA 0.912 
 cis-4-decenoyl carnitine NA 0.9541 
Polyamine Metabolism 0.01079 N-acetylputrescine 0.5825 2E-05 
 4-acetamidobutanoate 0.8618 3E-05 
 acisoga 0.0002 0.0003 
 5-methylthioadenosine (MTA) NA 0.0433 
Alanine and Aspartate 
Metabolism 
0.02412 N-acetylaspartate (NAA) 0.0002 0.2634 
 asparagine 0.0009 0.9422 
 N-acetylalanine 0.9901 0.009 
 alanine NA 0.6529 
 aspartate NA 0.9677 
Purine Metabolism, 
(Hypo)Xanthine/Inosine 
containing 
0.04317 xanthine 2E-07 0.438 
 urate NA 0.0004 
 N1-methylinosine 0.0008 0.0144 
 AICA ribonucleotide NA 0.0066 
 allantoin NA 0.0934 
 hypoxanthine NA 0.6652 
Purine Metabolism, 
Adenine containing 
0.04317 N6-carbamoylthreonyladenosine 0.1735 7E-05 
 N6-succinyladenosine 0.1452 0.0005 
 N1-methyladenosine 0.8632 0.0006 
 adenine NA 0.4835 
 adenosine NA 0.5677 
 
adenosine 5'-monophosphate 
(AMP) NA 0.5988 
Pyrimidine Metabolism, 
Uracil containing 
0.04317 pseudouridine 0.1506 6E-05 
 N-acetyl-beta-alanine NA 0.0002 
 3-ureidopropionate 0.0175 0.0024 
 uridine NA 0.2684 
 5-methyluridine (ribothymidine) NA 0.5196 
 beta-alanine NA 0.8665 
    
    
    
Table S3. Pathway enrichment analysis results. Pathways analysed and enrichment p-values are 
given, as well as metabolites within each pathway and significance values from tests used to select 
metabolites considered to be disease-associated. HC v PAH, significance of PAH on metabolite levels 
after controlling for potential confounders by linear regression; Prognosis, weakest significance of 
metabolite association with survival by Cox analysis in discovery or validation cohorts. *probable 
metabolite identity, but unconfirmed (see methods).  
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Metabolite Area Sig. 95% CI 
3-hydroxy-3-methylglutarate 0.75 2.05E-04 0.63 - 0.86 
3-hydroxybutyrylcarnitine (2) 0.67 1.10E-02 0.54 - 0.79 
4-acetamidobutanoate 0.67 8.40E-03 0.56 - 0.79 
5,6-dihydrothymine 0.67 1.04E-02 0.55 - 0.79 
acetylcarnitine 0.65 2.80E-02 0.52 - 0.77 
C-glycosyltryptophan 0.66 1.82E-02 0.53 - 0.78 
fumarate 0.67 1.01E-02 0.55 - 0.79 
hexadecanedioate 0.65 2.32E-02 0.52 - 0.78 
malate 0.69 3.32E-03 0.58 - 0.81 
N1-methyladenosine 0.69 3.62E-03 0.57 - 0.81 
N2,N2-dimethylguanosine 0.69 4.70E-03 0.57 - 0.80 
N-acetylalanine 0.67 1.01E-02 0.55 - 0.79 
N-acetylmethionine 0.76 6.94E-05 0.66 - 0.87 
N-acetylputrescine 0.69 4.07E-03 0.57 - 0.81 
N-acetyltaurine 0.68 6.40E-03 0.56 - 0.80 
N-formylmethionine 0.67 8.63E-03 0.56 - 0.79 
X - 11564 0.65 2.16E-02 0.53 - 0.77 
X - 12127 0.65 2.43E-02 0.53 - 0.77 
X - 12472 0.65 2.32E-02 0.53 - 0.77 
X - 12688 0.68 5.26E-03 0.57 - 0.80 
X - 12739 0.68 7.75E-03 0.56 - 0.79 
X - 13737 0.66 1.45E-02 0.54 - 0.78 
X - 15503 0.68 5.89E-03 0.56 - 0.80 
X - 21796 0.70 3.03E-03 0.59 - 0.80 
X - 24020 0.67 1.15E-02 0.55 - 0.78 
X - 24527 0.67 8.63E-03 0.55 - 0.79 
X - 24766 0.67 1.07E-02 0.55 - 0.78 
 
Table S4. ROC analysis of serial metabolite measurements. Area under the curve values for the 
association between metabolite level changes (i.e. sample 1 subtracted from sample 2) and survival 
during follow-up are shown for significantly associated metabolites. *probable metabolite identity, 
but unconfirmed (see methods). 
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 Controls PAH (19-70) PAH (>70) 
 n=30 n=69 n=8 
Female:Male ratio 2.0 2.3 3.0 
Age 48.5 +/- 13.1 48.3 +/- 14.1 75.6 +/- 8.1 
Angiogenin conc., ng/ml 360 +/- 110.3 479.7 +/- 176.6 554.9 +/- 234.2 
N2,N2-dimethylguanosine -0.1 +/- 1 1.6 +/- 1.2 2.7 +/- 1.4 
 
Table S5. Demographics and circulating factor levels in subjects used for angiogenin study. 
Mean +/- standard deviation is shown for continuous variables.  
 
 
 
 
 
Fig. S1. Metabolite levels in BMRP2 mutation carriers. (A) Average metabolite levels in PAH 
BMPR2 mutation carriers, non-carriers and control subjects for 20 metabolites found to significantly 
distinguish PAH and both healthy and disease controls, independent of potential confounders. (B) 
Correlation of average metabolite levels in BMPR2 mutation carriers and non-carriers relative to 
controls for 53 metabolites that distinguish PAH from healthy controls, independent of potential 
A B
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confounders.  Values plotted are z-scores calculated based on mean and standard deviation of all 
healthy volunteers in study - negative values indicate metabolites at lower levels in patients versus 
healthy controls and positive values indicate higher levels of metabolites in patients. *probable 
metabolite identity, but unconfirmed (see methods). 
 
 
Fig. S2– Survival analysis of PAH patients. (A) Receiver operating characteristic (ROC) curve for 
N2,N2-dimethylguanosine in the discovery cohort at 3 years of follow-up. The optimal cut-off for 
high/low risk levels of N2,N2-dimethylguanosine was derived from this for B&C. Kaplan Meier 
survival estimates in PAH patients in the discovery (B) and first validation (C) cohorts.  
 
N at risk
<1.83 SD 123 120 108 79 25
>1.83 SD 63 58 46 31 15
N at risk
<1.83 SD 79 73 57 36 24
>1.83 SD 65 56 39 21 13
A B
C
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Fig. S3. Dehydroisoandrosterone-sulphate (DHEA-S). Plasma DHEA-S levels in the discovery 
cohort are shown for healthy controls (HC) and PAH (19-70) with (A) separation by gender and (B) 
against age.  
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